Post-Infectious IBS Management

Initial Diagnostic Confirmation and Risk Stratification

The American Gastroenterological Association recommends repeat fecal calprotectin measurement to distinguish transient post-infectious inflammation from persistent pathology, as single elevated values may represent false positives with rates of 18-26% in asymptomatic patients 1
Calprotectin >150 μg/g indicates active inflammatory disease requiring endoscopic assessment to exclude IBD, as the infection may have unmasked underlying disease 1, 3
The American Gastroenterological Association suggests that calprotectin 50-150 μg/g requires clinical correlation with symptoms; if asymptomatic, repeat in 3-6 months, but if symptomatic, proceed with endoscopic evaluation 1

The American College of Gastroenterology recommends providing patient education explaining PI-IBS as a disorder of gut-brain interaction with visceral hypersensitivity, persistent low-grade inflammation, and dysbiosis following infection 2, 4
Initiate regular physical exercise, which improves gastrointestinal symptoms with benefits lasting up to 5 years 4
The American Gastroenterological Association suggests starting soluble fiber supplementation (ispaghula 3-4g/day, gradually increasing) while avoiding insoluble fiber that may exacerbate symptoms 4
Consider mesalazine 800 mg three times daily for 30 days as targeted anti-inflammatory therapy, as low-grade inflammation predicts response to mesalazine in PI-IBS patients 2
Alternatively, use rifaximin 550 mg three times daily for 14 days for patients with diarrhea-predominant symptoms and elevated calprotectin 4
Offer cognitive behavioral therapy or mindfulness-based therapy early, particularly given that psychological factors (anxiety, depression, somatization) are major risk factors for PI-IBS development and perpetuate inflammation 2, 4

Reassess symptoms using validated tools (Gastrointestinal Symptom Rating Scale, Bristol Stool Form Scale) 2, 4
Repeat fecal calprotectin every 3-6 months in patients with initially elevated levels to monitor for disease evolution 1
Recognize that PI-IBS symptoms decrease over time with better prognosis than non-PI-IBS, though resolution may take years 2, 5

Do not assume all elevated calprotectin in PI-IBS represents benign inflammation—the infection may have unmasked underlying IBD requiring different management 1
Do not rely on CRP alone, as it is less sensitive than fecal calprotectin for detecting intestinal inflammation in this population 1
Do not overlook psychological comorbidities (anxiety, depression, neuroticism) that amplify symptom perception and perpetuate inflammation—these require concurrent treatment 2, 5